On Monday, DSW Inc. (NYSE:DSW)’s shares declined -6.89% to $24.99.
DSW Inc. (DSW), a leading branded footwear and accessories retailer, is happy to declare a new DSW to Bayfair Center on East 14th Street. The store will open on October 1, 2015.
The brand new store will be stocked with designer and name brand footwear and accessories for men and women at an extraordinary value. Twenty - one thousand pairs of men’s and women’s shoes will fill the 15,000 square feet space, making DSW the greatest shoe shopping destination in San Leandro, California right now. Ladies will be able to shop the latest fall trends counting a large assortment of boots and booties, retro style sneakers, comfort styles, and dressy pumps and heels. Guys will be able to get men’s casual and chukka boots, running shoes, dress shoes, and sneakers from their favorite brands.
DSW Inc., together with its auxiliaries, operates as a branded footwear and accessories retailer in the United States. The company operates through two segments, DSW and Associated Business Group.
Hanesbrands Inc. (NYSE:HBI)’s shares dropped -2.96% to $28.48.
HanesBrands (HBI), a leading marketer of everyday basic apparel under world-class brands in the Americas, Europe and Asia, declared that it is reaffirming its 2015 financial guidance in conjunction with its planned investor meetings and investor conference webcast recently at the Goldman Sachs Global Retailing Conference in New York City.
Hanes reaffirmed all of its full-year 2015 guidance issued July 30, 2015, with second-quarter results. Comprised Of in its guidance are expectations for net sales of slightly less than $5.9 billion, adjusted operating profit of about $855 million to $875 million, adjusted earnings per diluted share of about $1.61 to $1.66, and net cash from operating activities of about $550 million. As communicated in July, any potential effect that share repurchases may have on EPS results are not comprised of in the company’s full-year guidance.
Hanes began repurchasing company stock in the open market in the third quarter under its formerly declared share repurchase program and will report its repurchasing activity when announcing third-quarter results.
Hanesbrands Inc., a consumer goods company, designs, manufactures, sources, and sells a range of basic apparels for men, women, and children in the United States. The company operates through four segments: Innerwear, Activewear, Direct to Consumer, and International.
At the end of Monday’s trade, Gentex Corporation (NASDAQ:GNTX)‘s shares dipped -1.07% to $14.83.
Gentex Corporation ( GNTX) — Seeing what’s behind you is critical to safe driving, whether you’re in a passenger vehicle or one of the most technologically advanced racecars in the world. A new pioneering technology designed to improve rear vision recently took a step closer to reality after successfully debuting at the grueling 24 Hours of Le Mans on Nissan’s new GT-R LM NISMO race car. The system comprises of a tiny rearward-facing camera that feeds live video to a mirror-integrated display in order to optimize a vehicle’s rearward view.
Gentex Corporation, a leading supplier of vision-related technologies to the global automotive industry, developed the technology. The system was originally designed for application on passenger vehicles; however, the Company recently formed a partnership with the Nissan Motorsports Team, which allowed the system to be installed on Nissan’s new LM P1 race cars and thoroughly vetted under demanding race conditions.
Gentex Corporation designs, develops, manufactures, and markets automatic-dimming rearview mirrors and electronics for the automotive industry; dimmable aircraft windows for the aviation industry; and commercial smoke alarms and signaling devices for the fire protection industry worldwide.
Peregrine Pharmaceuticals (NASDAQ:PPHM), ended its Monday’s trading session with -1.00% loss, and closed at $0.990.
Peregrine Pharmaceuticals, Inc. (PPHM) (PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body’s immune system to fight cancer, recently declared financial results for the first quarter of fiscal year (FY) 2016 ended July 31, 2015, and offered an update on its advancing clinical pipeline and other corporate developments.
Clinical Development Highlights
- Peregrine and AstraZeneca reached a cancer immunotherapy clinical trial partnershipto evaluate bavituximab in combination with AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736). The planned Phase I/Ib trial will evaluate the safety and efficacy of bavituximab in combination with durvalumab in multiple solid tumors. Peregrine is working closely with AstraZeneca to finalize the trial design.
- Phase III SUNRISE clinical trial in non-small cell lung cancer (NSCLC) continues to enroll patients and remains on track to complete patient enrollment by end of calendar year 2015.
- Peregrine declared plans to expand the bavituximab clinical development program to comprise a Phase II trial to evaluate the combination of bavituximab and Opdivo® (nivolumab), an anti-PD-1 antibody, in formerly treated, metastatic NSCLC. This trial is predictable to be initiated by the end of calendar year 2015.
Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops monoclonal antibodies for the treatment and diagnosis of cancer in the United States and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
